WEIHAI SHIDAI MARINE BIOTECHNOLOGY CO., LTD.

shidaimarine.com

As Asia's most professional manufacturer of liquid seaweed fertilizer, SHIDAI MARINE has been - engaged in an agriculture research program for 6 years - focused on kelp business and industry for more than 20 years - equipped with professional enzymolysis equipment over 300 sets - cultivating on a Laminaria Japonica farming base covering 1,000 hectares With all these experience, technology and resources, SHIDAI MARINE thus developed a process to extract essential nutrients from fresh kelp cells, while ultimately preserving their bioactivity beneficial to plant growth and development. And LJ KELP is therefore created accordingly. Numerous research programs have proved that LJ KELP plays a positive and effective role, especially in promoting root growth, flowering and fruits initiation and stress resistance.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BIOTECHNOLOGY LEADER LUMINULTRA SUBMITS COVID-19 CLINICAL DIAGNOSTIC TESTING KIT FOR REGULATORY AUTHORIZATION IN U.S., CANADA

LuminUltra | September 14, 2020

news image

Canada-based biotechnology front-runner LuminUltra announced today that it has submitted its GeneCount® COVID-19 RT-qPCR Assay Kit (COVID-19 Assay) to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) and to Health Canada for an Interim Order (IO). With authorization to use this key testing component, LuminUltra, a leader in field-based molecular diagnostic testing for over 20 years, will provide a complete clinical COVID-19 testing solution that can be custom...

Read More

MedTech

ARBOR BIOTECHNOLOGIES ENTERS INTO AGREEMENT WITH ACUITAS THERAPEUTICS FOR LIPID NANOPARTICLE DELIVERY SYSTEM FOR USE IN RARE LIVER DISEASES

Arbor Biotechnologies Inc | August 29, 2022

news image

Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that it has entered into an agreement with Acuitas Therapeutics, a leader in the development of lipid nanoparticles. As part of the agreement, the companies will combine the optimized delivery of Acuitas' highly validated LNP technology with Arbor’s differentiated, proprietary CRISPR gene editing technology designed for use in vivo in patien...

Read More

FUJIFILM DIOSYNTH BIOTECHNOLOGIES TO SUPPORT COVID-19 VACCINE CANDIDATE MANUFACTURING

FUJIFILM Diosynth Biotechnologies | July 28, 2020

news image

FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, viral vaccines and gene therapies, announced today that its College Station, Texas, site will support COVID-19 vaccine candidate manufacturing, as part of Operation Warp Speed, a U.S. government program that aims to begin delivering millions of doses of a safe, effective vaccine for COVID-19 to the U.S. population.The Biomedical Advanced Research and Development Auth...

Read More

MedTech, Industrial Impact

ARGENX AND GENMAB ENTER PARTNERSHIP TO ADVANCE ANTIBODY THERAPIES IN IMMUNOLOGY AND ONCOLOGY

Globenewswire | April 18, 2023

news image

argenx SE and Genmab A/S announced that argenx and Genmab have entered into a collaboration agreement to jointly discover, develop and commercialize novel therapeutic antibodies with applications in immunology, as well as in oncology therapeutic areas. The multiyear collaboration will leverage the antibody engineering expertise and knowledge of disease biology of both companies to accelerate the identification and development of novel antibody therapeutic candidates with a goal to address ...

Read More
news image

BIOTECHNOLOGY LEADER LUMINULTRA SUBMITS COVID-19 CLINICAL DIAGNOSTIC TESTING KIT FOR REGULATORY AUTHORIZATION IN U.S., CANADA

LuminUltra | September 14, 2020

Canada-based biotechnology front-runner LuminUltra announced today that it has submitted its GeneCount® COVID-19 RT-qPCR Assay Kit (COVID-19 Assay) to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) and to Health Canada for an Interim Order (IO). With authorization to use this key testing component, LuminUltra, a leader in field-based molecular diagnostic testing for over 20 years, will provide a complete clinical COVID-19 testing solution that can be custom...

Read More
news image

MedTech

ARBOR BIOTECHNOLOGIES ENTERS INTO AGREEMENT WITH ACUITAS THERAPEUTICS FOR LIPID NANOPARTICLE DELIVERY SYSTEM FOR USE IN RARE LIVER DISEASES

Arbor Biotechnologies Inc | August 29, 2022

Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that it has entered into an agreement with Acuitas Therapeutics, a leader in the development of lipid nanoparticles. As part of the agreement, the companies will combine the optimized delivery of Acuitas' highly validated LNP technology with Arbor’s differentiated, proprietary CRISPR gene editing technology designed for use in vivo in patien...

Read More
news image

FUJIFILM DIOSYNTH BIOTECHNOLOGIES TO SUPPORT COVID-19 VACCINE CANDIDATE MANUFACTURING

FUJIFILM Diosynth Biotechnologies | July 28, 2020

FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, viral vaccines and gene therapies, announced today that its College Station, Texas, site will support COVID-19 vaccine candidate manufacturing, as part of Operation Warp Speed, a U.S. government program that aims to begin delivering millions of doses of a safe, effective vaccine for COVID-19 to the U.S. population.The Biomedical Advanced Research and Development Auth...

Read More
news image

MedTech, Industrial Impact

ARGENX AND GENMAB ENTER PARTNERSHIP TO ADVANCE ANTIBODY THERAPIES IN IMMUNOLOGY AND ONCOLOGY

Globenewswire | April 18, 2023

argenx SE and Genmab A/S announced that argenx and Genmab have entered into a collaboration agreement to jointly discover, develop and commercialize novel therapeutic antibodies with applications in immunology, as well as in oncology therapeutic areas. The multiyear collaboration will leverage the antibody engineering expertise and knowledge of disease biology of both companies to accelerate the identification and development of novel antibody therapeutic candidates with a goal to address ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us